Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. - Wikidata - awgldk - TriplyDB

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.

http://www.wikidata.org/entity/Q37544357

about

The role of cell-free DNA in predicting colorectal cancer prognosis.Precision oncology: neither a silver bullet nor a dream.Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis.FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer.A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report Drug resistance and new therapies in colorectal cancer

P2860

Q38637642-DADB06B1-1FD6-466E-99B4-65EDA21EC277 Q47737073-09EFD483-92A1-4B64-943B-E403C694B2AB Q49785414-3E1A7444-B35C-4939-9AA2-F92AF9B74650 Q52627284-7185C480-0F04-4356-B3B3-48E0D05BA7D2 Q55003485-91D6527E-91BD-48A2-AA70-8332B1723CF1 Q55342871-ADFCF32D-3A76-4E45-90EA-FD687D08FCDD Q55347051-D0FAAC8C-A20F-4681-8E30-48B3A77BAC75 Q58572639-EAB0D691-C574-469C-A901-E41FC5D43BEC Q58740344-D7C4FDFE-F0B8-4319-A15C-84DACE95B0B0

P2860

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.

http://www.wikidata.org/entity/Q37544357

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Randomized study of FOLFIRI pl ...... colorectal cancer-WJOG 6210G.

@en

Randomized study of FOLFIRI pl ...... colorectal cancer-WJOG 6210G.

@nl

type

label

Randomized study of FOLFIRI pl ...... colorectal cancer-WJOG 6210G.

@en

Randomized study of FOLFIRI pl ...... colorectal cancer-WJOG 6210G.

@nl

prefLabel

Randomized study of FOLFIRI pl ...... colorectal cancer-WJOG 6210G.

@en

Randomized study of FOLFIRI pl ...... colorectal cancer-WJOG 6210G.

@nl

P1433

Q37544357-28E80762-5BEE-4AE6-A78F-7BFF46ED6B25

P1476

Q37544357-09100DEF-AFF8-41CE-91A6-356716C55045

P2093

Q37544357-0E673EDA-F86E-42CF-A7E3-103FCCB28418

Q37544357-262BB9A3-F580-4E67-8D0A-E304E7B57AE0

Q37544357-3822D0C4-A4B5-464E-87F9-F55554270D85

Q37544357-3DFB58E7-EBAE-41AB-AD23-6DB1E21FAB12

Q37544357-6145B32C-94A4-459E-B5E4-25CBB448A3B4

Q37544357-62B599B0-2B85-4B83-92A0-3E3A972092D4

Q37544357-6A8082B4-14F7-4F6E-AD1E-352DB0530DD9

Q37544357-75219485-A88C-40D4-8DF2-2F7A2AF6A449

Q37544357-889368C0-FEFE-4C2B-B934-CFC08AD054A8

Q37544357-9564A9ED-884E-4AC1-9B16-014636EC42DC

P2860

Q37544357-00A71D12-CABC-4174-8C45-CAF9CA3733AF

Q37544357-053C1D54-8385-4905-A563-A8BCB6158358

Q37544357-209B49AE-C5FA-4BD1-AC55-4401ABD783E8

Q37544357-28A7A25F-CE81-496D-96BE-8DF08F8A6C58

Q37544357-3FC6A3CA-0C6F-44DA-A847-B5F6BBE5D4B7

Q37544357-4F2271E2-C5A9-4823-89F9-03B0C078B045

Q37544357-51C261EA-3B3B-4AFA-A17D-9A205FDA1524

Q37544357-7AFCC96C-DC83-4AAB-9C81-B802D07FDA95

Q37544357-7C2F4F85-05A9-4F4E-9485-E08F1F5896FF

Q37544357-7E0866D7-A217-4924-BB2E-E39937E1EB29

P304

Q37544357-F3F3CE13-46B7-44D3-959C-0382576D463F

P31

Q37544357-691603F1-90B6-426B-AA33-858C5A775427

P356

Q37544357-522E0CA9-2C1E-463E-875F-4EF9BF2911C8

P433

Q37544357-96FBD7E5-2737-4640-8F02-3033262B3255

P478

Q37544357-F55014DD-BCCC-4B2F-BC7A-27CF8CD52903

P577

Q37544357-14D67CFE-2E51-41D5-96EB-F66E986A55A9

P698

Q37544357-E0737F65-30A8-4AD2-A516-73820B27D8AF

P921

Q37544357-8332B589-D3FF-43BF-A37F-786658707519

Q37544357-A8704F4C-2658-4737-90B8-D82D71189C83

P932

Q37544357-4BC22A9E-7867-443F-8933-315740CEA922

P356

P1433

P1476

Randomized study of FOLFIRI pl ...... colorectal cancer-WJOG 6210G.

@en

P2093

Hiroyuki Okuda

http://www.w3.org/2001/XMLSchema#string

Ichinosuke Hyodo

http://www.w3.org/2001/XMLSchema#string

Kazuko Sakai

http://www.w3.org/2001/XMLSchema#string

Kazuto Nishio

http://www.w3.org/2001/XMLSchema#string

Kei Muro

http://www.w3.org/2001/XMLSchema#string

Kentaro Yamazaki

http://www.w3.org/2001/XMLSchema#string

Kimio Yonesaka

http://www.w3.org/2001/XMLSchema#string

Kohei Shitara

http://www.w3.org/2001/XMLSchema#string

Masahiro Tsuda

http://www.w3.org/2001/XMLSchema#string

Narikazu Boku

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data.

Molecular determinants of cetuximab efficacy.

P304

1843-1850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13098

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27712015

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5198953

http://www.w3.org/2001/XMLSchema#string